SCHEMBL2497830

SCHEMBL2497830

CCOC(=O)c1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3Cl)cn2)c1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BTK Q06187 16/20 0.75
BLK P51451 4/20 0.70
LCK P06239 10/20 0.70
CSF1R P07333 2/20 0.63
EGFR P00533 1/20 0.62
ERBB2 P04626 1/20 0.62
TEC P42680 1/20 0.62
TXK P42681 1/20 0.62
BMX P51813 1/20 0.62
JAK3 P52333 1/20 0.62
ERBB4 Q15303 1/20 0.62
JAK2 O60674 1/20 0.61
PDGFRB P09619 1/20 0.61
FGFR1 P11362 1/20 0.61
CYP2C9 P11712 1/20 0.61
BRAF P15056 1/20 0.61
EPHB4 P54760 1/20 0.61
PTK2 Q05397 1/20 0.61
MAPK14 Q16539 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2497726 0.87 BTK (0.83) BTKBLKLCKCSF1REGFR
SCHEMBL15998211 0.85 BTK (1.00) BTKBLKLCKCSF1RJAK2
SCHEMBL2500744 0.85 BTK (0.74) BTKBLKLCKCSF1REGFR
SCHEMBL2491995 0.85 CSF1R (0.84) BTKBLKLCKCSF1RJAK2
SCHEMBL2493840 0.84 BTK (0.79) BTKBLKLCKCSF1REGFR
SCHEMBL15998163 0.83 BTK (0.81) BTKBLKLCKCSF1REGFR
SCHEMBL14286496 0.83 CSF1R (0.75) BTKBLKLCKCSF1RJAK2
SCHEMBL12190189 0.83 BTK (0.71) BTKBLKLCKCSF1REGFR
SCHEMBL2495621 0.82 BTK (0.75) BTKBLKLCKCSF1REGFR
SCHEMBL2494570 0.81 CSF1R (0.81) BTKBLKLCKCSF1RJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 BTK 44/4885BLK 71/4885LCK 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.